Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
Arrowhead Pharmaceuticals has announced a $25M milestone payment from Amgen. This milestone was triggered by […]
Hundreds of Patients to Benefit From Revolutionary Lung Cancer Drug On The NHS
A revolutionary targeted drug for lung cancer will be made available to anyone who is […]
Owkin and Amgen Use AI to Improve Cardiovascular Risk Prediction
AI startup Owkin and Amgen have announced the results of a three-year project to use […]
Amgen Begins Construction On New Biomanufacturing Plant In Central Ohio
Amgen (NASDAQ:AMGN) today announced the groundbreaking of its newest biomanufacturing plant, located in New Albany, Ohio. The […]
Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases
Amgen (NASDAQ: AMGN) and Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company pioneering precision medicines for […]
FDA Approves Repatha ® (evolocumab) in Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Repatha ® (evolocumab) as an […]
Amgen to Acquire Privately Held Teneobio for $900 Million in Cash With Future Contingent Milestone Payments
Amgen (NASDAQ: AMGN) and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a […]
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced an agreement to jointly develop and […]
FDA Accepts Amgen's sNDA For Otezla ®
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more